PMED Share Price Speculation
The average liability due to impairment in India is roughly $4,000 per employee ($7,000 in North America). In total, substance abuse costs America’s employers more than $160 billion per year in accidents, lost productivity and related problems. https://dwiresourcecenter.org/index.php/what-does-alcohol-drug-use-cost-your-business/
Multiply this by 36,000 Hindalco employees and you’ve got $144 million in potential employee liability that you could eliminate with PMEDs technology. I’m giving a rough guess estimate but to me it seems like something like that would easily be worth $20 million per year, perhaps more (to potentially save $144M.... why not?) As Equity Guru says, the last thing Hindalco needs is for a stoned employee buggering up a $95,000 sheet of aluminum.
And that’s just ONE contract that we know is coming by approximately end of July. Tech Mahindra, a multi-billion dollar conglomerate already in 91 countries with 151,000 employees, will be reselling PMED's tech giving them instant global scale. Who knows how much higher this alone will shoot this thinly traded stock?
Take a typical and conservative PE ratio of 20 ($45k/month burn rate is negligible) and this $20 million contract gets you a $4.00 per share price. Many techs on the Nasdaq trade at multiples of 30 for $6.00 a share. And this is just this ONE contract that we know is coming end of July. We know they are working on so many more now. 400-600% by end of July sounds pretty good to me.
This isn’t even taking into consideration the Juiceworks contract they have and are about to roll out mass screening for Covid19 and all the other contracts they are working on as management says their sales team is working 24/7 on which on its own, could shoot this much much higher.
From their news release of April 22 "With the positive outcomes achieved to date, the company has been able to advance to the pilot stage with Hindalco."
We already know the results are successful! In fact The Unit Head Mr. Kailash Pandey at Aditya Aluminium ($48.3B revenue) parent of Hindalco Aluminum, tapped PMED for a quicker cannabis impairment commercial test at their flagship aluminum plant in India not only just because the clinical study of 3000 persons was showing overwhelming success, but also because he has seen PMEDs tech team do it before in terms of AI success at that plant and for his company.
In summary: The Hindalco head honcho loves PMED AI tech so much because he's seen it in action before as it helped them give preciseness to their coal chain, so he sped up the cannabis impairment study as well. We are in good with Hindalco and this is very a good thing.
Unlike other companies undergoing clinical trials for drugs in Phase 1-2-3 trials where you don't know what the outcome will be, we already know what the outcome will be. How much better does it get than that?
Now it’s possible PMED won’t divulge the $ amount of their contract so their competitors won’t get to know their pricing structure. But we will get the total dollar amounts of all contracts lumped together for the quarter once financials come out which is 60 days after quarter end.
Q2 = August 30
Q3 = November 30